ArticleFrontiers in immunology2021

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.

Zheng Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.